Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.77
PRXL's Cash to Debt is ranked higher than
60% of the 258 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. PRXL: 0.77 )
PRXL' s 10-Year Cash to Debt Range
Min: 0.17   Max: No Debt
Current: 0.77

Equity to Asset 0.32
PRXL's Equity to Asset is ranked higher than
55% of the 240 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.64 vs. PRXL: 0.32 )
PRXL' s 10-Year Equity to Asset Range
Min: 0.3   Max: 0.72
Current: 0.32

0.3
0.72
F-Score: 7
Z-Score: 3.78
M-Score: -3.09
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 9.14
PRXL's Operating margin (%) is ranked higher than
84% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.61 vs. PRXL: 9.14 )
PRXL' s 10-Year Operating margin (%) Range
Min: -1.77   Max: 8.8
Current: 9.14

-1.77
8.8
Net-margin (%) 6.07
PRXL's Net-margin (%) is ranked higher than
83% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. PRXL: 6.07 )
PRXL' s 10-Year Net-margin (%) Range
Min: -18.09   Max: 6.28
Current: 6.07

-18.09
6.28
ROE (%) 23.08
PRXL's ROE (%) is ranked higher than
97% of the 232 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. PRXL: 23.08 )
PRXL' s 10-Year ROE (%) Range
Min: -15.55   Max: 23.12
Current: 23.08

-15.55
23.12
ROA (%) 7.55
PRXL's ROA (%) is ranked higher than
89% of the 260 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. PRXL: 7.55 )
PRXL' s 10-Year ROA (%) Range
Min: -7.19   Max: 9.2
Current: 7.55

-7.19
9.2
ROC (Joel Greenblatt) (%) 58.82
PRXL's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.02 vs. PRXL: 58.82 )
PRXL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -7.63   Max: 58.04
Current: 58.82

-7.63
58.04
Revenue Growth (%) 18.40
PRXL's Revenue Growth (%) is ranked higher than
95% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. PRXL: 18.40 )
PRXL' s 10-Year Revenue Growth (%) Range
Min: 1   Max: 23.9
Current: 18.4

1
23.9
EBITDA Growth (%) 27.50
PRXL's EBITDA Growth (%) is ranked higher than
93% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. PRXL: 27.50 )
PRXL' s 10-Year EBITDA Growth (%) Range
Min: -10.9   Max: 56.3
Current: 27.5

-10.9
56.3
EPS Growth (%) 40.60
PRXL's EPS Growth (%) is ranked higher than
96% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.30 vs. PRXL: 40.60 )
PRXL' s 10-Year EPS Growth (%) Range
Min: -26.8   Max: 40.6
Current: 40.6

-26.8
40.6
» PRXL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

PRXL Guru Trades in Q4 2013

Steven Cohen 241,514 sh (+2044.88%)
Paul Tudor Jones 18,351 sh (+99.47%)
Vanguard Health Care Fund 4,805,700 sh (+63.66%)
Jim Simons 636,100 sh (+51.85%)
Ken Fisher 2,587,749 sh (-1.58%)
Chuck Royce 455,000 sh (-4.21%)
Joel Greenblatt 22,428 sh (-51.75%)
» More
Q1 2014

PRXL Guru Trades in Q1 2014

Joel Greenblatt 103,542 sh (+361.66%)
Jim Simons 645,300 sh (+1.45%)
Chuck Royce 455,000 sh (unchged)
Vanguard Health Care Fund 4,805,700 sh (unchged)
Steven Cohen Sold Out
Ken Fisher 2,534,004 sh (-2.08%)
Paul Tudor Jones 5,600 sh (-69.48%)
» More
Q2 2014

PRXL Guru Trades in Q2 2014

Joel Greenblatt 287,113 sh (+177.29%)
Paul Tudor Jones 9,100 sh (+62.5%)
Jim Simons 736,900 sh (+14.19%)
Vanguard Health Care Fund 5,077,400 sh (+5.65%)
Chuck Royce 455,000 sh (unchged)
Ken Fisher 2,475,274 sh (-2.32%)
» More
Q3 2014

PRXL Guru Trades in Q3 2014

Joel Greenblatt 774,370 sh (+169.71%)
Chuck Royce 455,000 sh (unchged)
Vanguard Health Care Fund 5,077,400 sh (unchged)
Ken Fisher 2,427,492 sh (-1.93%)
Jim Simons 719,600 sh (-2.35%)
Paul Tudor Jones 7,000 sh (-23.08%)
» More
» Details

Insider Trades

Latest Guru Trades with PRXL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 Add 169.71%0.31%$52.97 - $64.26 $ 53.67-6%774370
Joel Greenblatt 2014-06-30 Add 177.29%0.12%$43.94 - $55.47 $ 53.677%287113
Joel Greenblatt 2014-03-31 Add 361.66%0.07%$45.18 - $56.94 $ 53.675%103542
Vanguard Health Care Fund 2013-12-31 Add 63.66%0.26%$38.93 - $54.85 $ 53.6718%4805700
Joel Greenblatt 2013-12-31 Reduce -51.75%0.04%$38.93 - $54.85 $ 53.6718%22428
Joel Greenblatt 2013-09-30 Reduce -57.22%0.12%$46.43 - $51.33 $ 53.6710%46486
Joel Greenblatt 2013-03-31 Reduce -25.52%0.07%$29.59 - $39.54 $ 53.6754%115560
Joel Greenblatt 2012-09-30 Add 64.33%0.11%$26.98 - $31.09 $ 53.6787%139526
Joel Greenblatt 2012-06-30 Add 37.93%0.05%$25 - $28.38 $ 53.67103%84905
Joel Greenblatt 2012-03-31 Add 165.31%0.09%$20.46 - $28.22 $ 53.67137%61558
Joel Greenblatt 2011-12-31 New Buy0.06%$18.26 - $22.63 $ 53.67166%23202
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 21.80
PRXL's P/E(ttm) is ranked higher than
91% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. PRXL: 21.80 )
PRXL' s 10-Year P/E(ttm) Range
Min: 6.48   Max: 52.08
Current: 21.8

6.48
52.08
P/B 5.10
PRXL's P/B is ranked higher than
69% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.37 vs. PRXL: 5.10 )
PRXL' s 10-Year P/B Range
Min: 0.98   Max: 6.08
Current: 5.1

0.98
6.08
P/S 1.30
PRXL's P/S is ranked higher than
89% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.06 vs. PRXL: 1.30 )
PRXL' s 10-Year P/S Range
Min: 0.33   Max: 1.77
Current: 1.3

0.33
1.77
PFCF 11.30
PRXL's PFCF is ranked higher than
98% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. PRXL: 11.30 )
PRXL' s 10-Year PFCF Range
Min: 9.43   Max: 99999999.99
Current: 11.3

9.43
99999999.99
EV-to-EBIT 14.28
PRXL's EV-to-EBIT is ranked higher than
91% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. PRXL: 14.28 )
PRXL' s 10-Year EV-to-EBIT Range
Min: -1612.8   Max: 238
Current: 14.28

-1612.8
238
PEG 1.07
PRXL's PEG is ranked higher than
97% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. PRXL: 1.07 )
PRXL' s 10-Year PEG Range
Min: 0.22   Max: 25.75
Current: 1.07

0.22
25.75
Shiller P/E 41.40
PRXL's Shiller P/E is ranked higher than
90% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. PRXL: 41.40 )
PRXL' s 10-Year Shiller P/E Range
Min: 19   Max: 428.17
Current: 41.4

19
428.17
Current Ratio 1.53
PRXL's Current Ratio is ranked higher than
59% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. PRXL: 1.53 )
PRXL' s 10-Year Current Ratio Range
Min: 1.21   Max: 3.36
Current: 1.53

1.21
3.36
Quick Ratio 1.53
PRXL's Quick Ratio is ranked higher than
62% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. PRXL: 1.53 )
PRXL' s 10-Year Quick Ratio Range
Min: 1.21   Max: 3.36
Current: 1.53

1.21
3.36

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 17.78
PRXL's Price/Tangible Book is ranked higher than
64% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.74 vs. PRXL: 17.78 )
PRXL' s 10-Year Price/Tangible Book Range
Min: 1.13   Max: 33.72
Current: 17.78

1.13
33.72
Price/DCF (Projected) 1.62
PRXL's Price/DCF (Projected) is ranked higher than
91% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. PRXL: 1.62 )
PRXL' s 10-Year Price/DCF (Projected) Range
Min: 1.44   Max: 8.33
Current: 1.62

1.44
8.33
Price/Median PS Value 1.32
PRXL's Price/Median PS Value is ranked higher than
70% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.32 vs. PRXL: 1.32 )
PRXL' s 10-Year Price/Median PS Value Range
Min: 0.39   Max: 4.36
Current: 1.32

0.39
4.36
Price/Peter Lynch Fair Value 1.17
PRXL's Price/Peter Lynch Fair Value is ranked higher than
97% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. PRXL: 1.17 )
PRXL' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.39   Max: 16.68
Current: 1.17

0.39
16.68
Price/Graham Number 4.08
PRXL's Price/Graham Number is ranked higher than
85% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. PRXL: 4.08 )
PRXL' s 10-Year Price/Graham Number Range
Min: 0.88   Max: 6.05
Current: 4.08

0.88
6.05
Earnings Yield (Greenblatt) 7.00
PRXL's Earnings Yield (Greenblatt) is ranked higher than
91% of the 253 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. PRXL: 7.00 )
PRXL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 14.1
Current: 7

0.4
14.1
Forward Rate of Return (Yacktman) 21.74
PRXL's Forward Rate of Return (Yacktman) is ranked higher than
90% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.35 vs. PRXL: 21.74 )
PRXL' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 3.3   Max: 36.3
Current: 21.74

3.3
36.3

Analyst Estimate

Jun15 Jun16 Jun17
Revenue(Mil) 2,183 2,362 2,580
EPS($) 2.70 3.14 3.52
EPS without NRI($) 2.70 3.14 3.52

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:PAX.Germany,
Parexel International Corp was incorporated in 1983. The Company provides clinical research, medical communications, consulting, commercialization and informatics and advanced technology services to the worldwide pharmaceutical, biotechnology, and medical device industries. The Company has three reporting segments: Clinical Research Services (CRS), PAREXEL Consulting and Medical Communications Services (PCMS), and Perceptive Informatics (Perceptive). CRS constitutes its core business and include all phases of clinical research from first-in-man trials, where a medicinal entity is tested on human subjects for the first time, through post-marketing studies, following approval by the presiding regulatory body. CRS service offerings include clinical trials management, observational studies, patient/disease registries and post-marketing surveillance, data management and biostatistics, epidemiology and health economics/outcomes research, clinical logistics, pharmacovigilance, and clinical pharmacology, as well as related medical affairs, patient recruitment, and investigator site services. PCMS provides technical expertise and advice in such areas as drug development, regulatory affairs, and good manufacturing practice (GMP) compliance consulting. In addition, PCMS provides a full spectrum of market development, product development, commercialization, and targeted communications services in support of product launch. PCMS consultants also identify alternatives and propose solutions to address clients' product development, registration, and commercialization issues. Additionally, PCMS provides reimbursement and market access (RMA) services. Perceptive provides information technology solutions designed to improve clients' product development processes. Perceptive's portfolio of products and services includes ClinPhone RTSM, medical imaging services, CTMS, EDC, web-based portals, systems integration, and patient diary applications. These solutions are sold individually or in combination, as elements of an eClinical suite. It competes with other biopharmaceutical services companies and other clinical research organizations (CROs) that provide one or more of the services being offered by it. Some of the biopharmaceutical services companies, such as Quintiles Transnational Corporation, Covance Inc., Pharmaceutical Product Development Inc., inVentiv Health, INC Research, and Icon plc, offer services that compete directly with its services at many levels.
» More Articles for PRXL

Headlines

Articles On GuruFocus.com
Parexcel: Great Growth but a Tough Business Aug 17 2011 
PAREXEL International Corp. (PRXL) Senior VP & CFO James F Jr Winschel sells 12,920 Shares Mar 11 2011 
PAREXEL International Corp. (PRXL) Senior VP & CFO James F Jr Winschel sells 1,500 Shares Mar 11 2011 
PAREXEL International Corp. Reports Operating Results (10-Q) Feb 09 2011 
PAREXEL International Corp. Reports Operating Results (10-Q) Nov 09 2010 
PAREXEL International Corp. Reports Operating Results (10-K/A) Sep 09 2010 
PAREXEL International Corp. Reports Operating Results (10-K) Aug 27 2010 
PAREXEL International Corp. Reports Operating Results (10-Q) May 07 2010 
PAREXEL International Corp. (PRXL) Senior VP & CFO James F Jr Winschel sells 13,149 Shares Mar 12 2010 
PAREXEL International Corp. (PRXL) Senior VP & CFO James F Jr Winschel sells 15,600 Shares Mar 04 2010 

More From Other Websites
Nasdaq stocks posting largest percentage decreases Dec 17 2014
PAREXEL International Announces Date Of Second Quarter Fiscal Year 2015 Earnings Release And... Dec 17 2014
PAREXEL International Announces Date Of Second Quarter Fiscal Year 2015 Earnings Release And... Dec 17 2014
PAREXEL ClinPhone® RTSM Named Leader Of Interactive Response Technology In New Benchmark Report... Dec 15 2014
PAREXEL INTERNATIONAL CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Dec 09 2014
PAREXEL INTERNATIONAL CORP Financials Nov 11 2014
PAREXEL Expands Clinical Trial Supply And Logistics Services Through Opening Of New European... Nov 11 2014
PAREXEL International to Present at Jefferies Global Healthcare Conference Nov 10 2014
Insider Trading Alert - PRXL, SCOR And HLF Traded By Insiders Nov 07 2014
PAREXEL International Beats Q1 Earnings, Misses Revenues Nov 07 2014
10-Q for PAREXEL International Corp. Nov 05 2014
PAREXEL International To Present At Credit Suisse Healthcare Conference Nov 04 2014
PAREXEL INTERNATIONAL CORP Files SEC form 10-Q, Quarterly Report Nov 03 2014
Market Thorns, Roses, All Time Highs, and ETF All Time Highs... Oct 30 2014
Mid-Afternoon Market Update: NASDAQ Climbs 0.55%; Terex Shares Slide After Weak Earnings Oct 30 2014
Stocks Improve In Afternoon Trading; Taser Surges On Earnings Oct 30 2014
Mid-Day Market Update: Dow Jumps More Than 150 Points; Visa Shares Gain On Upbeat Earnings Oct 30 2014
PAREXEL International (PRXL) Stock Lower After Weak Fiscal 2015 First Quarter Revenue Results Oct 30 2014
Mid-Morning Market Update: Markets Mixed; MasterCard Earnings Beat Estimates Oct 30 2014
Stocks Turn Mixed As Dow Rises; Gentherm Tumbles As F5 Rises Oct 30 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK